The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries

Matičič, Mojca; Pirnat, Z.; Leicht, Astrid; Zimmermann, Ruth; Windelinck, T.; Jauffret‐Roustide, Marie; Duffell, Erika; Tammi, Tuukka; Schatz, Eberhard

doi:10.1186/s12954-020-00439-3

Cited by 13 publications

(11 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Efforts to reach PWIDs are unsuccessful in many countries. Better organized interventions are urgently needed since additional factors, like HIV infection and alcohol abuse that contribute to the progress of fibrosis, are commonly involved[ 359 , 360 ]. This is exemplified by a longitudinal study of 501 patients from an opioid agonist therapy program.…”

Section: Hcv/hiv Coinfectionmentioning

confidence: 99%

Hepatitis C virus: A critical approach to who really needs treatment

Voumvouraki¹

2022

WJH

View full text Add to dashboard Cite

Introduction of effective drugs in the treatment of hepatitis C virus (HCV) infection has prompted the World Health Organization to declare a global eradication target by 2030. Propositions have been made to screen the general population and treat all HCV carriers irrespective of the disease status. A year ago the new severe acute respiratory syndrome coronavirus 2 virus appeared causing a worldwide pandemic of coronavirus disease 2019 disease. Huge financial resources were redirected, and the pandemic became the first priority in every country. In this review, we examined the feasibility of the World Health Organization elimination program and the actual natural course of HCV infection. We also identified and analyzed certain comorbidity factors that may aggravate the progress of HCV and some marginalized subpopulations with characteristics favoring HCV dissemination. Alcohol consumption, HIV coinfection and the presence of components of metabolic syndrome including obesity, hyperuricemia and overt diabetes were comorbidities mostly responsible for increased liver-related morbidity and mortality of HCV. We also examined the significance of special subpopulations like people who inject drugs and males having sex with males. Finally, we proposed a different micro-elimination screening and treatment program that can be implemented in all countries irrespective of income. We suggest that screening and treatment of HCV carriers should be limited only in these particular groups.

show abstract

Section: Hcv/hiv Coinfectionmentioning

confidence: 99%

Hepatitis C virus: A critical approach to who really needs treatment

Voumvouraki¹

2022

WJH

View full text Add to dashboard Cite

show abstract

“…(4) Widespread Endometriosis Awareness Campaigns. Undoubtedly, targeted public health awareness campaigns improved awareness of HIV, HCV, T2DM, and mental illness among health systems, health care providers, and the general population [81][82][83][84][85][86][87][88]. They also modified negative societal beliefs and attitudes toward their respective marginalized populations.…”

Section: Recommendationsmentioning

confidence: 99%

Stigma and Endometriosis: A Brief Overview and Recommendations to Improve Psychosocial Well-Being and Diagnostic Delay

Sims

Gupta

Missmer

et al. 2021

IJERPH

View full text Add to dashboard Cite

Endometriosis is a chronic gynecological disease that affects approximately 1 in 10 women of reproductive age. Symptoms of severe pelvic pain, infertility, fatigue, and abnormal menstruation can cause significant negative effects on an individual’s physical and mental health, including interactions with their family, friends, and health care providers. Stigma associated with endometriosis has been under-studied and is rarely discussed in current literature. Herein, this paper aims to provide a brief overview of published literature to explore and establish the plausibility of stigma as a driver of suboptimal psychosocial well-being and diagnostic delay among individuals living with endometriosis. We present the clinical characteristics and physical and mental health consequences associated with endometriosis, highlight several theoretical constructs of stigma, and review the limited studies documenting women’s lived experiences of endometriosis-related stigma. To mitigate harmful effects of this phenomenon, we recommend increasing efforts to assess the prevalence of and to characterize endometriosis-related stigma, implementing awareness campaigns, and developing interventions that combat the multidimensional negative effects of stigma on timely care, treatment, and quality of life for individuals living with endometriosis.

show abstract

“…There remains a need to scale up harm reduction services for the prevention of HBV and HCV among PWID, as there was evidence of suboptimal implementation among the countries reporting 2017 data. This is likely due to political and legal environments that criminalise PWID, stigma and discrimination against PWID, and insufficient funding for harm reduction programmes, despite gradual progress towards an improved harm reduction policy environment and good evidence of the cost-saving nature of these interventions [17][18][19].…”

Section: Plos Global Public Healthmentioning

confidence: 99%

Monitoring progress towards elimination of hepatitis B and C in the EU/EEA

Sharrock

Noori

Axelsson

et al. 2022

PLOS Glob Public Health

View full text Add to dashboard Cite

This paper presents data on selected indicators to show progress towards elimination goals and targets for hepatitis B and hepatitis C in the 31 countries of the European Union (EU) and European Economic Area (EEA). A monitoring system was developed by the European Centre for Disease Prevention and Control, which combined newly collected data from EU/EEA countries along with relevant data from existing sources. Data for 2017 were collected from the EU/EEA countries via an online survey. All countries provided responses. In 2017, most countries reporting data had not reached prevention targets for childhood hepatitis B vaccination and for harm reduction services targeting people who inject drugs (PWID). Four of 12 countries had met the target for proportion of people living with chronic HBV diagnosed and seven of 16 met this target for hepatitis C. Data on diagnosed cases treated were lacking for hepatitis B. Of 12 countries reporting treatment data for hepatitis B, only Iceland met the target. This first collection of data across the EU/EEA highlighted major issues with data completeness and quality and in the indicators that were used, which impairs a clear overview of progress towards the elimination of hepatitis. The available data, whilst incomplete, suggest that as of 2017, the majority of the EU/EEA countries were far from meeting most of the 2020 targets, in particular those relating to harm reduction and diagnosis. It is critical to improve the data collected in order to develop more effective services for hepatitis prevention, diagnosis, and treatment that are needed in order to meet the 2030 elimination targets.

show abstract

The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries

Cited by 13 publications

References 19 publications

Hepatitis C virus: A critical approach to who really needs treatment

Hepatitis C virus: A critical approach to who really needs treatment

Stigma and Endometriosis: A Brief Overview and Recommendations to Improve Psychosocial Well-Being and Diagnostic Delay

Monitoring progress towards elimination of hepatitis B and C in the EU/EEA

Contact Info

Product

Resources

About